Literature DB >> 31563518

Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

Sumanta Pal1, Siwen Hu-Lieskovan2, Neeraj Agarwal2.   

Abstract

Entities:  

Year:  2019        PMID： 31563518     DOI： 10.1016/S1470-2045(19)30619-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

Review 1.  Harnessing cytokines and chemokines for cancer therapy.

Authors:  David J Propper; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2022-01-07       Impact factor: 65.011

2.  Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.

Authors:  Nizar M Tannir; Kyriakos P Papadopoulos; Deborah J Wong; Raid Aljumaily; Annie Hung; Manuel Afable; Jong Seok Kim; David Ferry; Alexandra Drakaki; Johanna Bendell; Aung Naing
Journal:  Int J Cancer       Date:  2021-03-24       Impact factor: 7.396
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.